A cohort study found a high risk of end-stage kidney disease associated with acromegaly

[1]  Cheol-Young Park,et al.  Risk of Neurodegenerative Diseases in Patients With Acromegaly , 2022, Neurology.

[2]  T. Okamura,et al.  Impact of hypertension and diabetes on the onset of chronic kidney disease in a general Japanese population , 2022, Hypertension Research.

[3]  E. Huang,et al.  11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[4]  D. Haffner,et al.  Renal effects of growth hormone in health and in kidney disease , 2021, Pediatric Nephrology.

[5]  T. Yoo,et al.  Association of Longitudinal Trajectories of Systolic BP with Risk of Incident CKD: Results from the Korean Genome and Epidemiology Study. , 2020, Journal of the American Society of Nephrology : JASN.

[6]  E. Choi.  Cardiovascular Research Using the Korean National Health Information Database , 2020, Korean circulation journal.

[7]  M. Grams,et al.  Chronic Kidney Disease Diagnosis and Management: A Review. , 2019, JAMA.

[8]  J. Yoon,et al.  The cumulative incidence and trends of rare diseases in South Korea: a nationwide study of the administrative data from the National Health Insurance Service database from 2011–2015 , 2019, Orphanet Journal of Rare Diseases.

[9]  M. Fleseriu,et al.  Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. , 2018, Endocrine reviews.

[10]  Ki-Up Lee,et al.  Association Between Diabetic Retinopathy and Parkinson Disease: The Korean National Health Insurance Service Database , 2018, The Journal of clinical endocrinology and metabolism.

[11]  K. Arita,et al.  Treatable glomerular hyperfiltration in patients with active acromegaly. , 2016, European journal of endocrinology.

[12]  R. Wanke,et al.  Growth hormone (GH)‐transgenic insulin‐like growth factor 1 (IGF1)‐deficient mice allow dissociation of excess GH and IGF1 effects on glomerular and tubular growth , 2016, Physiological reports.

[13]  M. Ravera,et al.  Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[14]  Ki-Up Lee,et al.  Data Analytic Process of a Nationwide Population-Based Study Using National Health Information Database Established by National Health Insurance Service , 2016, Diabetes & metabolism journal.

[15]  J. S. Lee,et al.  Cohort Profile Cohort Profile : The National Health Insurance Service – National Sample Cohort ( NHIS-NSC ) , South Korea , 2017 .

[16]  L. Bach,et al.  Insulin-like growth factors and kidney disease. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  Young Duk Song,et al.  Background and Data Configuration Process of a Nationwide Population-Based Study Using the Korean National Health Insurance System , 2014, Diabetes & metabolism journal.

[18]  P. Chanson,et al.  Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. , 2014, Endocrine reviews.

[19]  P. Chanson,et al.  Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciuria? , 2012, The Journal of clinical endocrinology and metabolism.

[20]  M. D. De Martino,et al.  The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission. , 2010, European journal of endocrinology.

[21]  V. Salomaa,et al.  Risk factors for end‐stage renal disease in a community‐based population: 26‐year follow‐up of 25 821 men and women in eastern Finland , 2009, Journal of internal medicine.

[22]  S. Grottoli,et al.  Microalbuminuria in insulin sensitivity in patients with growth hormone-secreting pituitary tumor. , 2008, The Journal of clinical endocrinology and metabolism.

[23]  J. Griffith,et al.  Cardiovascular disease and subsequent kidney disease. , 2007, Archives of internal medicine.

[24]  K. Reynolds,et al.  A population-based, prospective study of blood pressure and risk for end-stage renal disease in China. , 2007, Journal of the American Society of Nephrology : JASN.

[25]  A. Kessler,et al.  High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism. , 2003, American journal of physiology. Renal physiology.

[26]  F. Chiarelli,et al.  Growth hormone and IGF-I in diabetic children with and without microalbuminuria. , 1999, Diabetes, nutrition & metabolism.

[27]  G. Striker,et al.  IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy. , 1999, Diabetes.

[28]  M. Lawson,et al.  Contribution of Growth Hormone and IGF-I to Early Diabetic Nephropathy in Type 1 Diabetes , 1998, Diabetes.

[29]  T. Abribat,et al.  Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. , 1991, JAMA.

[30]  M. Krempf,et al.  Effect of long-acting somatostatin analog (SMS 201-995) on high glomerular filtration rate in insulin dependent diabetic patients. , 1990, International journal of clinical pharmacology, therapy and toxicology.

[31]  D. Aron,et al.  Synthesis and binding of insulin-like growth factor I by human glomerular mesangial cells. , 1989, The Journal of clinical endocrinology and metabolism.

[32]  G. Striker,et al.  Synthesis and release of insulinlike growth factor I by mesangial cells in culture. , 1988, The American journal of physiology.

[33]  OUP accepted manuscript , 2021, European Heart Journal.

[34]  R. Menon,et al.  Growth hormone and chronic kidney disease , 2019, Current opinion in nephrology and hypertension.

[35]  S. Melmed.  Chapter 15 – Acromegaly , 2017 .

[36]  B. Schreiber,et al.  Insulin-like growth factor-1 stimulates production of mesangial cell matrix components. , 1995, Clinical nephrology.